RayzeBio

Explore the latest insights on RayzeBio and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of RayzeBio’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on RayzeBio and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of RayzeBio's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps
CompanyDeals

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607; SHA: 601607) announced that it has renewed its Sales and Distribution Agreement with Shanghai Fudan‑Zhangjiang Bio‑Pharmaceutical Co., Ltd. (HKG: 1349). Under the agreement,…

Gilead Q3 Product Sales Jump 13% to USD 8.3 Billion as HIV Franchise Grows 18%; Full‑Year Guidance Raised to USD 31.0–31.3 Billion

Gilead Q3 Product Sales Jump 13% to USD 8.3 Billion as HIV Franchise Grows 18%; Full‑Year Guidance Raised to USD 31.0–31.3 Billion

HutchMed's Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC

HutchMed’s Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
BMS's RYZ101 Meets Primary Endpoint in Phase 3 ACTION‑1 Trial – Alpha‑Emitting Radiopharmaceutical Shows Significant PFS Benefit in Post‑Lu177 GEP‑NETs
CompanyDrug

BMS’s RYZ101 Meets Primary Endpoint in Phase 3 ACTION‑1 Trial – Alpha‑Emitting Radiopharmaceutical Shows Significant PFS Benefit in Post‑Lu177 GEP‑NETs

Philochem Grants RayzeBio Global Rights to OncoACP3 for Prostate Cancer
CompanyDeals

Philochem Grants RayzeBio Global Rights to OncoACP3 for Prostate Cancer

BMS Regains Exclusive Rights to ABZ-706 in Greater China
CompanyDeals

BMS Regains Exclusive Rights to ABZ-706 in Greater China

CompanyDeals

BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition

CompanyDeals

Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership